OPK

OPKO Health announced an agreement to sell select BioReference assets to Labcorp for $722 million in cash plus up to $150 million in earnouts. The deal includes the 4Kscore Test, specialty testing operations, and over 80 patient service centers.

OPKO aims to focus on its biopharmaceutical business, while Labcorp expects $250 million in first-year revenue from the acquisition. OPK stock rose 17.5% following the announcement.

Solventum Corporation (SOLV) received FDA 510(k) clearance for combining its Restrata Synthetic Electrospun Fiber Matrix with V.A.C. Therapy for advanced wound care. The clearance strengthens SOLV's competitive position in the advanced wound care market, which is projected to reach $19.32 billion by 2030. The combined therapy may reduce dressing changes, streamline workflows, and support recurring revenue growth, though commercial impact depends on market adoption.

Fresenius Medical Care (FMS) announced the U.S. launch of its FDA-cleared multiFiltratePRO System for treating acute kidney injury in critically ill patients. The integrated continuous kidney replacement therapy system automates regional citrate anticoagulation procedures in ICUs.

FMS stock gained 3.1% following the announcement. The company plans a phased U.S. rollout targeting growth in the hospital-based acute kidney care market, with the global CRRT market expected to grow at 8.2% CAGR through 2034.

GE HealthCare announced five new global clinical collaborations to evaluate its StarGuide GX digital SPECT/CT system, a next-generation nuclear medicine imaging platform using advanced detector technology and NVIDIA computing. The system has received CE Mark approval in Europe but awaits FDA clearance in the US. The collaborations with leading institutions aim to advance quantitative imaging, dynamic imaging, and theranostics applications, supporting GEHC's competitive positioning in the growing precision oncology market.

Revvity announced the launch of Signals LabGistics, an AI-first software solution designed to connect and orchestrate scientific workflows across pharmaceutical, biotechnology, and specialty chemical companies. The platform converts natural-language instructions into coordinated workflows, integrates with existing lab systems, and will be available in major markets by December 2026. The announcement follows Revvity's recent acquisitions and product launches in diabetes screening and cell models.

Becton, Dickinson and Company (BD) announced positive nine-month results from the AGILITY trial for its Revello Vascular Covered Stent in treating iliac artery disease. The trial met its primary endpoint with a 2.8% failure rate, 97.2% primary patency, and 98.3% freedom from clinically driven target lesion revascularization.

The device remains investigational in the U.S. with clinical follow-up continuing through 36 months. The global iliac stent market is projected to grow at a 6.5% CAGR through 2033.

Doximity announced an extension of its 13-year partnership with U.S. News & World Report, continuing to provide physician data for Doctor Finder, Patient Connect appointment-booking tools, and Expert Opinion surveys for hospital rankings. The partnership leverages Doximity's network of 3+ million medical professionals to connect patients with healthcare providers. Despite the news, DOCS stock declined 2.1% following the announcement and is down 32.4% year-to-date.

Glaukos Corporation (GKOS) shares have gained 36.8% over six months, outperforming its industry, driven by strong Q2 results with 50% revenue growth to $185.6 million, successful commercial expansion of Epioxa for keratoconus treatment, positive clinical data for iDose TR, and pipeline advances including a new retinal disease licensing agreement. The company raised its 2026 revenue guidance to $680-$700 million.

BrightSpring Health Services (BTSG) has surged 67.3% year-to-date, outperforming broader markets, driven by strong growth in Specialty and Infusion revenues (up 32.7%) and Provider Services (up 29.1%). The company raised its 2026 outlook twice and improved leverage to 2.15x after divesting its Community Living business.

However, a $200M IRA impact on Home and Community Pharmacy and integration execution risks present headwinds. Analysts rate BTSG as a Hold.

QuidelOrtho Corporation (QDEL) shows strong Q2 2026 results with 21% adjusted EBITDA growth and expanding margins, supported by a diversified product portfolio and $50 million cost-saving initiatives through 2027. However, weak respiratory demand and overdependence on this segment pose risks, with the company adopting a cautious outlook for the 2026-2027 respiratory season.

Hims & Hers Health has launched Hers, its women's health platform, in Australia by rebranding Juniper from its Eucalyptus acquisition. The platform offers personalized care for hair regrowth, menopause, and weight management with 24/7 support. The expansion leverages Eucalyptus' local presence to strengthen brand recognition and recurring revenue in the growing Australian telehealth market, which is projected to grow at 18.2% CAGR through 2034.

Avantor (AVTR) reported strong second-quarter 2026 results with raised 2026 guidance, driven by VWR segment's return to 1.7% organic growth and BMP's double-digit order growth. However, BMP's continued 5.6% organic revenue decline and uneven demand recovery remain concerns. The company's Revival program shows execution improvements across commercial performance and operations.

AMN Healthcare is positioned for growth driven by rising healthcare staffing demand, technology investments, and higher-margin services, with Nurse and Allied revenues up 11% and Passport users growing 33%. However, persistent pricing competition, weakness in physician and technology segments, and earnings normalization pose significant headwinds to sustained performance.

Bruker Corporation (BRKR) shares gained 66.3% over the past year, driven by strong demand in biopharma, diagnostics, and mass spectrometry. However, the company faces a $134.9M goodwill impairment, currency headwinds, and restructuring costs. Full-year 2026 revenue guidance was lowered to $3.54-$3.57B due to currency pressures, though the company maintains a solid financial position with $184.9M in cash.

10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies for biomarker discovery in bladder cancer and residual disease detection in acute myeloid leukemia. The company will utilize its Flex Apex and Xenium platforms to identify treatment response markers. Despite the strategic partnership, TXG stock declined 5.6% following the announcement, though it has gained 366.6% year-to-date.

Waters Corporation (WAT) is positioned for growth driven by sustained analytical sciences demand, BD acquisition integration, and product innovation. The company projects 10.9% year-over-year earnings growth for 2026 with $50 million in revenue synergies and $75 million in cost savings expected. However, weakness in China diagnostics, BD integration execution risks, and dependence on customer capital spending present headwinds.

Becton, Dickinson and Company (BD) announced a landmark partnership with the U.S. Government to invest $19 billion in domestic manufacturing expansion, including $3 billion toward manufacturing capacity. The company aims to increase domestically supplied essential medical consumables to 80% and manufacture all U.S.-used needles domestically with American-made steel. The agreement provides tariff protection on covered products, though financial impact remains unquantified pending finalization of tariff rates and implementation timing.

Globus Medical (GMED) reported strong Q2 2026 performance with musculoskeletal revenues rising 7.5% and base business sales up 10.9%. The company continues to gain market share through product innovation, with over 60 development projects underway.

However, foreign exchange volatility remains a concern. GMED maintains a debt-free balance sheet with $507.7 million in cash, supporting continued R&D and expansion investments.